Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) serves as a guide to treat and manage different severity classes of patients with COPD. It was suggested that the five categories of FEV1 % predicted (GOLD 0–4), can be applied for selecting different therapeutic approaches. However, validation of these selective properties is very poor. To determine the relevance of the GOLD staging system for estimating the severity of clinical problems, GOLD 2 (n=70) and GOLD 3 (n=65) patients were drawn from a prospective cohort of patients with COPD and evaluated crosssectionally by a newly developed Nijmegen Integral Assessment Framework (NIAF). The NIAF is a detailed assessment of a wide range of aspects of health status (HS). Significant, though small, differences were found in Static Lung Volumes, Exercise Capacity, Subjective Pulmonary Complaints, Subjective Impairment, and Health-Related QoL, besides Airflow of course. Moreover, overlap between scores of these five HS sub-domains was substantial, indicating small clinical relevance for discernment. No significant differences were found in nine other aspects of HS. It is concluded that GOLD stages do not discriminate in any aspect of HS other than airflow obstruction, and therefore do not help the clinician in deciding which treatment modalities are appropriate

Nontuberculous Mycobacteria in Respiratory Tract Infections, Eastern Asia

To characterize the distribution of nontuberculous mycobacteria (NTM) species isolated from pulmonary samples from persons in Asia and their association with pulmonary infections, we reviewed the literature. Mycobacterium avium complex bacteria were most frequently isolated (13%–81%) and were the most common cause of pulmonary NTM disease (43%–81%). Also pathogenic were rapidly growing mycobacteria (M. chelonae, M. fortuitum, M. abscessus). Among all NTM isolated from pulmonary samples, 31% (582/1,744) were considered clinically relevant according to American Thoracic Society diagnostic criteria. Most patients were male (79%) and had a history of tuberculosis (37%). In Asia, high prevalence of rapidly growing mycobacteria and a history of tuberculosis are distinct characteristics of pulmonary NTM disease. This geographic variation is not well reflected in the American Thoracic Society criteria for NTM infections and could be incorporated in future guidelines

Clinical Relevance of Nontuberculous Mycobacteria, Oman

Little is known about the clinical relevance of nontuberculous mycobacteria (NTM) in the Arabian Peninsula. We assessed the prevalence and studied a random sample of isolates at a reference laboratory in Muscat, Oman. NTM cause disease in this region, and their prevalence has increased

Clinical Relevance of Nontuberculous Mycobacteria, Oman

Little is known about the clinical relevance of nontuberculous mycobacteria (NTM) in the Arabian Peninsula. We assessed the prevalence and studied a random sample of isolates at a reference laboratory in Muscat, Oman. NTM cause disease in this region, and their prevalence has increased

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers

© 2020 Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs); they act as aerosol reservoirs, allowing the user to actuate the pMDI device and then inhale the medication in a 2-step process that helps users overcome challenges in coordinating pMDI actuation with inhalation. Both spacers and VHCs have been shown to increase fine particle delivery to the lungs, decrease oropharyngeal deposition, and reduce corticosteroid-related side effects such as throat irritation, dysphonia, and oral candidiasis commonly seen with the use of pMDIs alone. Spacers and VHCs are not all the same, and also are not interchangeable: the performance may vary according to their size, shape, material of manufacture and propensity to become electrostatically charged, their mode of interface with the patient, and the presence or otherwise of valves and feedback devices. Thus, pairing of a pMDI plus a spacer or a VHC should be considered as a unique delivery system. In this Rostrum we discuss the risk potential for a patient getting switched to a spacer or VHC that delivers a reduced dose medication

Recommendations for the measurement of FIV(1) values in chronic obstructive pulmonary disease.

Contains fulltext : 71226.pdf (publisher's version ) (Closed access)BACKGROUND: In contrast to static inspiratory parameters such as vital capacity and inspiratory capacity, information on forced inspiratory volume in 1 s (FIV(1)) in patients with chronic obstructive pulmonary disease (COPD) is limited. OBJECTIVES: It was the aim of this study to investigate the influence of the preceding expiratory manoeuvre and the optimal number of manoeuvres on FIV(1) values. METHODS: In 169 patients with COPD, FIV(1) manoeuvres were performed after a forced (FIV(1)-Fe) and a slow (FIV(1)-Se) expiration. To investigate the optimal number of the FIV(1)-Se manoeuvres, 8 attempts were performed. RESULTS: The variability of FIV(1)-Fe was greater than that of FIV(1)-Se. The mean difference between FIV(1)-Se and FIV(1)-Fe was 0.21 litres (p < 0.01) and dependent on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage. The higher the GOLD stage, the greater the difference between the 2 techniques. The correlation coefficient between FIV(1)-Se and FIV(1)-Fe was high (r = 0.89, p = 0.01), but there was a poor agreement between these parameters (limits of agreement -0.52 to 0.94 litres). Five manoeuvres were needed to obtain an optimal FIV(1)-Se. There was no association with the GOLD stage. CONCLUSIONS: In COPD patients, FIV(1)-Se are less variable than FIV(1)-Fe, the agreement between the 2 manoeuvres is poor, and at least 5 FIV(1)-Se manoeuvres are needed to get an acceptable FIV(1). This holds for all GOLD stages

Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999-2007.

Contains fulltext : 89514.pdf (publisher's version ) (Closed access

Reply to letter to the Editor

Item does not contain fulltex